Nonpharmacologic effects of botulinum toxin on the life quality of patients with spasmodic dysphonia

被引:8
|
作者
Anari, Shahram
Carding, Paul N.
Hawthorne, Maurice R.
Deakin, Jayne
Drinnan, Michael J.
机构
[1] James Cook Univ Hosp, Dept Otolaryngol Head & Neck Surg, Middlesbrough, Cleveland, England
[2] Freeman Rd Hosp, Dept Speech Pathol, Newcastle Upon Tyne, Tyne & Wear, England
[3] James Cook Univ Hosp, Dept Speech Pathol, Middlesbrough, Cleveland, England
[4] Freeman Rd Hosp, Dept Phys Med, Newcastle Upon Tyne, Tyne & Wear, England
来源
LARYNGOSCOPE | 2007年 / 117卷 / 10期
关键词
spasmodic dysphonia; quality of life; botulinum toxin;
D O I
10.1097/MLG.0b013e3180de4d63
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective: Botulinum toxin (BT) injection improves objective and subjective voice measurements in spasmodic dysphonia; however, it is not clear whether the results are entirely caused by the neuromuscular blocking effects of BT or whether other factors (e.g., psychological or emotional) play a part. The aim of this study is to investigate whether nonpharmacologic factors contribute to the changes observed in the quality of life (QoL) after BT treatment of spasmodic dysphonia. Study Design: Prospective cohort study. Methods: Thirty-eight consecutive spasmodic dysphonic patients attending for repeat BT injections were investigated by recording their Voice Handicap Index (VHI) scores at three time points: 1) immediately prior to injection (baseline), 2) 1 day postinjection (when least pharmacologic change is expected), and 3) 2 weeks postinjection (when most pharmacologic change is expected). The changes in the total and domain VHI scores were compared between the two postinjection scores and the baseline value using two-way analysis of variance and the post hoc Bonferroni test. Results: Most of the change in VHI score occurred between the baseline and first postinjection measurement. For two of the domains (total and emotional), the change was statistically significant. The change between the two postinjection. assessments was minimal, and no domain showed statistically significant change. Conclusions: Our data indicate that the early improvements in QoL after BT injection can only in small part be attributed to the neurotoxic effects of the agent. We cannot say whether the reported effects in our study are attributable to a strong placebo response or are a real consequence of the patient's changing emotional state.
引用
收藏
页码:1888 / 1892
页数:5
相关论文
共 50 条
  • [21] Longitudinal Follow-Up of Adductor Spasmodic Dysphonia Patients After Botulinum Toxin Injection: Quality of Life Results
    Paniello, Randal C.
    Barlow, Jamie
    Serna, Jannie S.
    LARYNGOSCOPE, 2008, 118 (03): : 564 - 568
  • [22] Factors Influencing Botulinum Toxin Dose Instability in Spasmodic Dysphonia Patients
    Rosow, David E.
    Pechman, Amanda
    Saint-Victor, Sandra
    Lo, Kaming
    Lundy, Donna S.
    Casiano, Roy R.
    JOURNAL OF VOICE, 2015, 29 (03) : 352 - 355
  • [23] Botulinum toxin injection and airflow stability in spasmodic dysphonia
    Cantarella, G
    Berlusconi, A
    Maraschi, B
    Ghio, A
    Barbieri, S
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2006, 134 (03) : 419 - 423
  • [24] SPASMODIC DYSPHONIA - EMOTIONAL STATUS AND BOTULINUM TOXIN TREATMENT
    MURRY, T
    CANNITO, MP
    WOODSON, GE
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1994, 120 (03) : 310 - 316
  • [25] The point-touch technique for botulinum toxin injection in adductor spasmodic dysphonia: quality of life assessment
    Morzaria, S.
    Damrose, E. J.
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2011, 125 (07): : 714 - 718
  • [26] THE TREATMENT OF ADDUCTOR SPASMODIC DYSPHONIA USING BOTULINUM TOXIN
    WHURR, R
    FONTANA, H
    LORCH, M
    BROOKES, G
    LEES, A
    FOLIA PHONIATRICA, 1992, 44 (1-2): : 90 - 91
  • [27] BOTULINUM TOXIN INJECTION OF THE VOCAL FOLD FOR SPASMODIC DYSPHONIA
    MILLER, RH
    WOODSON, GE
    JANKOVIC, J
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1987, 113 (06) : 603 - 605
  • [28] THE USE OF BOTULINUM TOXIN IN THE TREATMENT OF ADDUCTOR SPASMODIC DYSPHONIA
    WHURR, R
    LORCH, M
    FONTANA, H
    BROOKES, G
    LEES, A
    MARSDEN, CD
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1993, 56 (05): : 526 - 530
  • [29] Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients - an Australian experience
    Tisch, SHD
    Brake, HM
    Law, M
    Cole, IE
    Darveniza, P
    JOURNAL OF CLINICAL NEUROSCIENCE, 2003, 10 (04) : 434 - 438
  • [30] Spasmodic dysphonia: Clinical features, associated conditions, and effects of Botulinum toxin therapy in 169 patients
    Tisch, SH
    Brake, HM
    Law, MG
    Darveniza, P
    NEUROLOGY, 2000, 54 (07) : A198 - A198